On 19 June 2026, the United States announced that it will cease funding South Africa’s HIV/AIDS programmes after claims that the South African government has failed to protect the white‑minority Afrikaner community.
The $400 million a year contribution, which had been delivered via the President’s Emergency Fund for Aids Relief (Pepfar), will be phased out starting this year. Washington argues that the policy requests put forward by the White House have not been met – including concerns about racially discriminatory program design and links to Iran – and that South Africa’s status as a middle‑income nation warrants greater self‑reliance.
South Africa’s health ministry, which was not informed of the decision in advance, says it has been working toward a self‑reliance plan and that most antiretroviral drugs are funded domestically. It notes that Pepfar has only supported a fifth of the country’s total HIV programme spending.
The move comes months after President Donald Trump issued an executive order criticizing South Africa for perceived policies that undermine “equal opportunities” for racially disfavoured landowners. Trump also accused the country of “white genocide” and set up a limited refugee programme for Afrikaners, an allegation that the South African government disputes as unsubstantiated.
The withdrawal of U.S. aid is part of a broader cooling in the relations between the two nations, which included a U.S. boycott of South Africa’s G20 summit and various diplomatic spats over policy disagreements since the inauguration of the Trump administration.
With more than 8 million South Africans living with HIV – the highest national prevalence in the world – the funding gap could strain an already over‑taxed public health infrastructure. South Africa’s government will need to reallocate resources to maintain treatment and prevention programmes now.
The US State Department confirmed that the philanthropic “bridge plan” put in place last October will now be replaced by a phased drawdown, with the intention of reducing dependency while encouraging domestic funding.
Western media and advocacy groups are watching closely to see how the withdrawal will affect treatment rollout timelines and whether local health authorities can fill the funding void.
